Melanocortin receptor agonist

PT-141 (Bremelanotide)

Bremelanotide (PT-141) is a melanocortin receptor agonist given by subcutaneous injection; FDA approved it as Vyleesi in 2019 for premenopausal women with acquired, generalized HSDD.1,2

Strong evidence (the app's grade, not a conclusion of the sources); FDA-approved for one indication, with sponsor-run efficacy trialsGet the app

Level after one dose

PT-141 (Bremelanotide) after one dose: 50% at ~2.5 h, 25% at 5 h, 12.5% at 7.5 h.

Drawn from the half-life in the app's model, ~2.5 h. The model's figures

The Vyleesi label describes bremelanotide acetate as a synthetic, cyclic heptapeptide with a molecular weight of 1025.2 (free base).2 PT-141 is the name used for the same compound in the trial literature, as in the title of a 2006 trial, "bremelanotide (PT-141), a melanocortin receptor agonist".3 Hadley and Dorr, in Peptides in 2006, called it "A new MTII analog", MTII being melanotan II.4 The app's notes describe it as a metabolite of melanotan II; Hadley and Dorr use the word analog.

FDA approved Vyleesi on June 21, 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD).1 The label states that Vyleesi "is not indicated for the treatment of HSDD in postmenopausal women or in men" and "is not indicated to enhance sexual performance".2 In the two phase 3 trials the label reports a mean change in the Female Sexual Function Index desire score of 0.5 against 0.2 (study 1) and 0.6 against 0.2 (study 2) for bremelanotide against placebo, no significant difference in satisfying sexual events, and discontinuation because of adverse reactions in 18% on bremelanotide against 2% on placebo.2

The label states that bremelanotide is a melanocortin receptor agonist that "nonselectively activates several receptor subtypes with the following order of potency: MC1R, MC4R, MC3R, MC5R, MC2R", and that at therapeutic dose levels "binding to MC1R and MC4R is most relevant".2 The label also states that MC1R is expressed on melanocytes and that binding at this receptor leads to melanin expression and increased pigmentation.2

In animals

In rats, Pfaus and colleagues (Proceedings of the National Academy of Sciences, 2004) reported that PT-141 "selectively stimulates solicitational behaviors in the female rat".5 Molinoff and colleagues (Annals of the New York Academy of Sciences, 2003) reported that administration of PT-141 to rats and nonhuman primates results in penile erections, and that systemic administration to rats activates neurons in the hypothalamus, shown by an increase in c-Fos immunoreactivity.6

3

Pharmacokinetics

Values from the Milligram app's model.

Half-life
~2.5 h
Bioavailability
95%
Typical dose
1–2 mg/day
Route
SubQ
Time to peak
~1 h

The app lists a half-life of about 2.5 hours, a bioavailability of 95% and a time to peak of about 1 hour for subcutaneous injection. The Vyleesi label and FDA's review give different values, set beside the app's in the table.

Table 3.1Pharmacokinetics5 rows
ParameterValueNote
Half-life~2.5 hoursThe label gives a mean terminal half-life of approximately 2.7 hours (range 1.9 to 4.0 hours) after a single subcutaneous dose.2 An FDA review of an interaction study gives a mean elimination half-life of ~2.7 to ~3 hours.1 After intranasal doses in healthy men, Diamond and colleagues reported a mean half-life of 1.85 to 2.09 hours.7
Bioavailability (subcutaneous)95%The label states that absolute bioavailability after subcutaneous administration was about 100%.2 FDA's clinical pharmacology review gives 114% and 116% for autoinjector and prefilled syringe in 36 healthy women, and states that this indicates complete absorption into the systemic circulation.1
Time to peak~1 hourThe label gives a median time to peak of approximately 1.0 hour (range 0.5 to 1.0 hours).2 In the phase 2b trial, median times to peak were 0.50, 0.50 and 0.58 hours after 0.75, 1.25 and 1.75 mg.8
Duration of effect~8 hours8 hours is the app's duration figure. The label states: "The duration of efficacy after each dose is unknown."2
Distribution and metabolism21% protein bound; 25.0 LThe label gives a volume of distribution of 25.0 ± 5.8 L, and states that the primary metabolic pathway involves multiple hydrolyses of the amide bond of the cyclic peptide.2

The chart is an illustrative model built from the app's half-life of 2.5 hours and time to peak of 1 hour, not measured blood levels. The every-24-hours interval is the once-daily dosing the label gives for its open-label ambulatory blood pressure study of 127 premenopausal women; the label's description of that study gives no dose.2

Level over 3 days

Interval between doses

Level, as a share of the peak after one 1.75 mg dose

As studied: every 24 hours2.

An illustration from a pharmacokinetic model using a half-life of 2.5 hours. It is not a measured level or a suggested dose.

4

Human studies

Table 4.1Human studies5 rows
Study and yearDesignPeopleDose and lengthMain result
Diamond and colleagues, 20063Randomized, double-blind crossover; called preliminary by the authors18 premenopausal women with female sexual arousal disorderA single intranasal 20 mg dose or placebo, in each of two clinic sessionsMore women reported moderate or high sexual desire after bremelanotide than after placebo (P = 0.0114); a trend toward more positive feelings of genital arousal (P = 0.0833); more of those who attempted intercourse within 24 hours were satisfied with their arousal (P = 0.0256); vaginal vasocongestion did not change significantly.
Clayton and colleagues, 20169Phase 2b, randomized, double-blind, placebo-controlled dose-finding; funded by Palatin Technologies397 randomized premenopausal women with female sexual dysfunctions; 327 in the efficacy population0.75, 1.25 or 1.75 mg subcutaneously, as desired, over 12 weeksSatisfying sexual events a month, 1.25 and 1.75 mg pooled against placebo: +0.7 against +0.2 (p = 0.0180); 0.75 mg did not differ from placebo.
Kingsberg and colleagues, 2019 (RECONNECT 301 and 302)10Two identical phase 3 randomized, double-blind, placebo-controlled trials; sponsored by Palatin Technologies1,267 randomized, 1,202 in the efficacy population; mean age 391.75 mg subcutaneously as needed, 24 weeksGreater change than placebo in desire score (0.35, integrated) and in distress item 13 (−0.33); no significant difference in satisfying sexual events.
Simon and colleagues, 2019 (open-label extension)11Uncontrolled 52-week open-label extension; every woman took bremelanotide, no comparator arms; descriptive analyses; funded by Palatin Technologies and AMAG Pharmaceuticals684 of 856 eligible women elected to take part; 272 of the 684 completed1.75 mg subcutaneously as neededDesire-domain score change from the core phase's baseline to the end of the extension: 1.25 to 1.30 in women who took bremelanotide in the core phase, 0.70 to 0.77 in women switched from placebo; distress item 13: −1.4 to −1.7 and −0.9; no new safety signals.
Spana and colleagues, 202212Two phase 1 randomized, double-blind, placebo-controlled trials; funded by Palatin TechnologiesPremenopausal women with a body mass index above 30 kg/m²; Study A 30 on bremelanotide and 28 on placebo, Study B 27Study A: three injections a day for 15 days (up to 2.5 mg); Study B: crossover, three 4-day periodsStudy A (per-protocol): body weight 1.3 kg lower than placebo at day 16 (95% CI −1.9 to −0.8 kg); Study B: 1.7 against 0.9 kg with twice-daily dosing, once-daily not significant (p = .0805); 3 of 30 and 12 of 27 withdrew; the authors name short duration and small numbers as limitations.

Deeper analysis: the RECONNECT phase 3 trials

Kingsberg and colleagues (Obstetrics and Gynecology, 2019) reported two identical randomized, double-blind, placebo-controlled phase 3 trials, RECONNECT studies 301 and 302, of bremelanotide 1.75 mg administered subcutaneously as needed in premenopausal women with hypoactive sexual desire disorder.10 Exclusions included pregnancy or nursing, any other female sexual dysfunction, and depression, psychosis, bipolar disorder or substance abuse diagnosed or treated within 6 months before screening.10 Of the 1,267 women randomized, 1,247 formed the safety population and 1,202 the modified intent-to-treat efficacy population, and the authors note that the majority of the study population was white and non-Hispanic.10

The coprimary endpoints were the change from baseline to end of study in the desire domain of the Female Sexual Function Index (FSFI-D) and in item 13 of the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO), which asks about feeling bothered by low sexual desire.10 Relative to placebo, desire scores rose by 0.30 in study 301 (P <.001) and 0.42 in study 302 (P <.001), and distress scores fell by 0.37 (P <.001) and 0.29 (P =.005); the integrated differences were 0.35 and −0.33 (both P <.001).10

The key secondary endpoint, satisfying sexual events, did not differ between groups (integrated: bremelanotide 0.0, placebo −0.1, P =.630).10 A post hoc exploratory analysis in the paper reported that 25.0% of sexual encounters were satisfying on bremelanotide against 9.8% on placebo (P <.001).10 Withdrawal differed between groups: the authors report 41.9% on bremelanotide against 16.0% on placebo in study 301 and 43.8% against 28.4% in study 302, and state that "a differential study withdrawal rate was observed in both studies".10 The label gives premature discontinuation among the modified intent-to-treat patients as 40% against 13% in study 1 and 39% against 25% in study 2.2

The authors write that "the safety and efficacy of bremelanotide has yet to be established in postmenopausal women and in women whose comorbidities include psychiatric disorders requiring medication".10

Palatin Technologies sponsored the trials, and the paper states that the sponsor "had a role in the design, execution, analysis, reporting, and funding of the studies".10 The disclosures state that Williams and Krop are employees and stockholders of AMAG, Jordan is a vice president and stockholder of Palatin, and Lucas was a Palatin employee at the time of the study; Kingsberg and Clayton report advisory or consulting work for AMAG and Palatin among other companies.10

Spielmans (Journal of Sex Research, 2021) re-analyzed the trials from the FDA New Drug Application and wrote that 72.72% of protocol-listed outcomes were not reported by Kingsberg and colleagues, that the meta-analysis found similar results to theirs, and that adverse event-induced study discontinuation was "substantially higher on bremelanotide" (OR = 11.98, 95% CI = 3.74-38.37).13 Spielmans and Ellefson (Journal of Sex Research, 2024) wrote that bremelanotide's benefits "are statistically modest and limited to outcomes for which scant evidence of validity among women with HSDD exists".14

Deeper analysis: the phase 2b dose-finding trial

Clayton and colleagues (Women's Health, 2016) screened 1142 patients at 67 US and Canadian clinical sites; 397 were randomized, 327 formed the modified intent-to-treat efficacy population (women with at least one at-home dose and an assessment after the first 4 weeks) and 293 completed the study.9 The primary endpoint was the change in satisfying sexual events a month, and the primary analysis pooled the 1.25 and 1.75 mg groups against placebo: +0.7 against +0.2 (p = 0.0180).9 The Female Sexual Function Index total score (+3.6 against +1.9, p = 0.0017) and the FSDS-DAO total score (−11.1 against −6.8, p = 0.0014) were secondary endpoints; the first secondary measure in the hierarchical testing, the FSDS-DAO arousal score, was not statistically significant, so the authors state that all secondary endpoints were considered exploratory and their p-values nominal.9 Palatin Technologies funded the study; Spana, Lucas and Jordan, whose listed affiliation is Palatin, are employees and stockholders of Palatin, and the other eight authors, Clayton among them, report research support or consulting fees from Palatin among other companies.9

White and colleagues (Journal of Hypertension, 2017) reported ambulatory blood pressure data from the same 397 women, who had normotension or controlled hypertension; women with uncontrolled treated or untreated hypertension were excluded, which the authors call an important limitation.8 After two doses 24 hours apart, systolic pressure rose relative to placebo by 2.4 and 3.0 mmHg at 1.25 mg (P values 0.029 and 0.076) and by 3.1 and 3.2 mmHg at 1.75 mg (P values 0.006 and 0.027) in the 0 to 4 hour interval; peak increases typically lasted less than 15 minutes, and heart rate was 4.6 to 4.7 beats a minute lower at 1.75 mg.8 Twenty-six participants discontinued because of prespecified blood pressure increases, in similar proportions across the four groups.8 Palatin supported the study, Jordan and Lucas are full-time Palatin employees, and White was the study's medical monitor and was compensated by Palatin for that role.8

Earlier work in men and a retracted trial

Rosen and colleagues (International Journal of Impotence Research, 2004) gave subcutaneous PT-141 at 0.3 to 10 mg to healthy men, with a statistically significant erectile response at doses greater than 1.0 mg, and 4 or 6 mg to men with erectile dysfunction who reported an inadequate response to Viagra, with a statistically significant response at both doses.15

The Journal of Sexual Medicine retracted a 2008 trial of bremelanotide in women with arousal disorder by Safarinejad; the retraction notice states that "we can no longer verify the results or methods as presented and therefore retract the article".16 The Journal of Urology attached a 2023 expression of concern to Safarinejad and Hosseini's 2008 trial, "Salvage of Sildenafil Failures With Bremelanotide".17

5

Doses reported in studies and on labels

The app's typical dose is 1 to 2 mg a day. The label states 1.75 mg administered subcutaneously in the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity.2

Table 5.1Doses reported in studies and on labels5 rows
SourceRouteDose reportedContext
Label, 20242Subcutaneous autoinjector1.75 mg (1.75 mg/0.3 mL)As needed; one dose within 24 hours at most; more than 8 doses a month is not recommended
Kingsberg and colleagues, 201910Subcutaneous autoinjector1.75 mgAs needed, no more than one dose per 24 hours and a maximum of 12 doses in each 4-week period; 24 weeks
Clayton and colleagues, 20169Subcutaneous prefilled syringe0.75, 1.25 and 1.75 mgAs desired, 12 weeks
Spana and colleagues, 202212SubcutaneousStudy A: 1.25 mg then two 1.0 mg doses on day 1, then 2.5 mg and two 2.0 mg doses a day; Study B: three treatments given twice daily in each period, 0 mg/0 mg, 2.5 mg/0 mg (once-daily bremelanotide) or 2.5 mg/2.0 mg (twice-daily)Obese women; 15 days (Study A), three 4-day periods (Study B)
Diamond and colleagues, 20063Intranasal20 mgSingle dose per session, 18 women

The label's Table 1 gives the adverse reactions reported in at least 2% of patients in the bremelanotide group, at an incidence greater than in the placebo group, in the pooled randomized, double-blind phase 3 trials (bremelanotide n = 627, placebo n = 620). It lists eleven reactions.2

Table 6.1Side effects reported11 rows
ReactionBremelanotide 1.75 mg, %Placebo, %
Nausea40.01.3
Flushing20.30.3
Injection site reactions13.28.4
Headache11.31.9
Vomiting4.80.2
Cough3.31.3
Fatigue3.20.5
Hot flush2.70.2
Paraesthesia2.60.0
Dizziness2.20.5
Nasal congestion2.10.5

The label's footnote defines injection site reactions as including injection site pain, unspecified injection site reactions, erythema, hematoma, pruritus, hemorrhage, bruising, paresthesia and hypoesthesia.2

Clayton and colleagues (Journal of Women's Health, 2022) give flushing as 20.3% against 1.3% on placebo and injection site reactions as 5.4 against 0.5, where the label's table gives flushing as 20.3% against 0.3% and injection site reactions as 13.2% against 8.4%; the paper's summary text does not state its definitions or the unit of the injection site figures.18 Serious adverse reactions were reported in 1.1% of bremelanotide-treated and 0.5% of placebo-treated patients.2 Clayton and colleagues describe a development program of 3500 subjects in 43 completed studies and state that there were no deaths.18

On nausea, the label states that it was reported in 40% of bremelanotide-treated patients, required anti-emetic therapy in 13% and led to premature discontinuation in 8%, and that incidence was highest after the first dose (21% of patients) and declined to about 3% after subsequent doses.2 In a phase 4 trial of 228 healthy women, oral ondansetron 8 mg given 30 minutes before a single 1.75 mg dose made no significant difference to the incidence of nausea.2 Kingsberg and colleagues report that seven bremelanotide patients had 10 treatment-emergent serious adverse events and three placebo patients had four, and that one serious event in study 301, vomiting and headache followed by overnight hospitalization, was considered related to the study drug.10

Blood pressure and heart rate: the label states that in clinical studies bremelanotide induced maximal increases of 6 mmHg in systolic and 3 mmHg in diastolic blood pressure that peaked between 2 to 4 hours post dose, with a heart rate reduction of up to 5 beats per minute, and that blood pressure and heart rate usually returned to baseline within 12 hours.2 The label lists uncontrolled hypertension and known cardiovascular disease as contraindications.2

Focal hyperpigmentation: the label states that it was reported in 1% of patients who received up to 8 doses a month, including involvement of the face, gingiva and breasts, compared with no placebo-treated patients.2 In another clinical study, 38% of patients developed focal hyperpigmentation after daily dosing for 8 days, and an additional 14% of those who continued for 8 more consecutive days developed new focal pigmentary changes.2 The label states that patients with dark skin were more likely to develop it and that resolution was not confirmed in all patients after discontinuation.2 In Spana and colleagues' study of obese women, skin hyperpigmentation was reported by 19 of 30 (63.3%) on bremelanotide against 2 of 28 (7.1%) on placebo during three injections a day for 15 days.12

Other label entries: one case of acute hepatitis in the open-label extension in a woman who had received 10 doses over one year, with transaminases above 40 times the upper limit of normal, where the label states that "the role of VYLEESI could not definitively be excluded" and liver tests returned to normal 4 months after discontinuation.2

Kingsberg and colleagues report that no clinically significant effects on clinical laboratory tests, electrocardiograms, weight, depression or suicidal ideation were observed in either phase 3 study.10 The label states that a 20 mg intranasal dose "does not prolong the QTc interval to any clinically relevant extent".2

Body weight was the outcome of Spana and colleagues' two phase 1 trials in women with a body mass index above 30 kg/m², funded by Palatin Technologies; Jordan and Spana are Palatin employees and Fischkoff was one at the time.12 In Study A, per-protocol body weight on day 16 was 1.3 kg lower than placebo (95% CI −1.9 to −0.8 kg; p < .0001) and mean caloric intake about 400 kcal a day lower (p < .01); 3 of 30 on bremelanotide withdrew, 2 for adverse events (hypertension and nausea).12 In Study B, 12 of 27 withdrew: 6 for blood pressure criteria (4 on the once-daily regimen) and 3 for adverse events.12 Mean weight fell 1.7 kg on twice-daily bremelanotide against 0.9 kg on placebo (p < .001), and the once-daily difference did not reach significance (p = .0805).12

FDA approved Vyleesi on June 21, 2019; the label's indication is the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder, characterized by low sexual desire that causes marked distress or interpersonal difficulty and not due to a co-existing medical or psychiatric condition, problems with the relationship, or the effects of a medication or drug substance.1,2 The label states that safety and effectiveness have not been established in pediatric or geriatric patients, and that treatment be discontinued after 8 weeks if the patient reports no improvement.2 The label lists Cosette Pharmaceuticals, Inc. as the marketer.2

The text of the WADA 2026 Prohibited List, read on 16 November 2026, returned no match for bremelanotide, PT-141 or melanocortin.19 Its S2 class, peptide hormones, growth factors, related substances and mimetics, prohibits the listed substances "and other substances with similar chemical structure or similar biological effect(s)"; the text read does not say how that wording applies to bremelanotide.19

9

Storage and handling

Sources in this part

  1. 2Cosette Pharmaceuticals, 2024

The label supplies Vyleesi as 1.75 mg of bremelanotide in 0.3 mL solution in a single-dose, disposable prefilled autoinjector.2 Its storage statement is: "Store at or below 25°C (77°F). Do not freeze. Protect from light."2

The label states that the mechanism by which Vyleesi improves HSDD in women is unknown, and that the duration of efficacy after each dose is unknown.2 On 16 November 2026 the PubMed query bremelanotide[tiab] (title or summary text) returned 96 records, and the query bremelanotide[tiab] AND (randomized[tiab] OR trial[tiab]) returned 26. The sources cited give no regulatory status for Australia or the European Union. The pivotal efficacy trials were sponsored by Palatin Technologies, and two re-analyses by Spielmans, the second with Ellefson, question the reporting of outcomes and the validity of the efficacy measures.10,13,14

What is the half-life of PT-141?

The app lists the half-life of PT-141 (bremelanotide) as about 2.5 hours. The Vyleesi label gives a mean terminal half-life of approximately 2.7 hours (range 1.9 to 4.0 hours) after a single subcutaneous dose.2

Is PT-141 FDA approved?

Yes: FDA approved Vyleesi (bremelanotide) on June 21, 2019 for premenopausal women with acquired, generalized hypoactive sexual desire disorder.1

What is the bioavailability of PT-141?

The app lists the bioavailability of PT-141 as 95%. The label states that absolute bioavailability after subcutaneous administration was about 100%, and FDA's clinical pharmacology review gives 114% and 116% for the autoinjector and prefilled syringe.2,1

How long does PT-141 take to reach its peak level?

The app lists the time to peak of PT-141 as about 1 hour. The label gives a median time to peak of approximately 1.0 hour (range 0.5 to 1.0 hours).2

What are the side effects of PT-141 in trials?

In the pooled phase 3 trials, the label reports nausea in 40.0% on bremelanotide against 1.3% on placebo, flushing in 20.3% against 0.3%, injection site reactions in 13.2% against 8.4%, headache in 11.3% against 1.9% and vomiting in 4.8% against 0.2%.2 Discontinuation because of adverse reactions was 18% on bremelanotide and 2% on placebo.2

Does PT-141 raise blood pressure?

In the label's clinical studies, bremelanotide induced maximal increases of 6 mmHg in systolic and 3 mmHg in diastolic blood pressure that peaked between 2 to 4 hours post dose, with blood pressure usually returning to baseline within 12 hours.2

Is PT-141 the same as melanotan II?

Hadley and Dorr (Peptides, 2006) described PT-141 as "A new MTII analog", MTII being melanotan II.4 The label lists focal hyperpigmentation under its warnings and precautions: it was reported in 1% of patients who received up to 8 doses a month, against no placebo-treated patients.2

Is PT-141 banned by WADA?

The text of the WADA 2026 Prohibited List, read on 16 November 2026, returned no match for bremelanotide, PT-141 or melanocortin.19 Its S2 class also prohibits "and other substances with similar chemical structure or similar biological effect(s)"; the text read does not say how that applies to bremelanotide.19

13

References

  1. US Food and Drug Administration. Multi-discipline review, NDA 210557, Vyleesi (bremelanotide). Center for Drug Evaluation and Research, 2019. FDA review, NDA 210557
  2. Cosette Pharmaceuticals, Inc. Vyleesi (bremelanotide injection), prescribing information. DailyMed, revised 10/2024. DailyMed label
  3. Diamond LE, et al. An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist. J Sex Med 2006. PMID 16839319
  4. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides 2006. PMID 16412534
  5. Pfaus JG, et al. Selective facilitation of sexual solicitation in the female rat by a melanocortin receptor agonist. Proc Natl Acad Sci U S A 2004. PMID 15226502
  6. Molinoff PB, et al. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci 2003. PMID 12851303
  7. Diamond LE, et al. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141 in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004. PMID 14963471
  8. White WB, et al. Usefulness of ambulatory blood pressure monitoring to assess the melanocortin receptor agonist bremelanotide. J Hypertens 2017. PMC5338879
  9. Clayton AH, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond) 2016. PMC5384512
  10. Kingsberg SA, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol 2019. PMC6819021
  11. Simon JA, et al. Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder. Obstet Gynecol 2019. PMC6819023
  12. Spana C, et al. Effect of bremelanotide on body weight of obese women: Data from two phase 1 randomized controlled trials. Diabetes Obes Metab 2022. PMC9314948
  13. Spielmans GI. Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. J Sex Res 2021. PMID 33678061
  14. Spielmans GI, Ellefson EM. Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. J Sex Res 2024. PMID 36809187
  15. Rosen RC, et al. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141 in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res 2004. PMID 14999221
  16. Safarinejad MR. RETRACTED: Evaluation of the safety and efficacy of bremelanotide, a melanocortin receptor agonist, in female subjects with arousal disorder. J Sex Med 2008. PMID 18179455
  17. Expression of Concern: Salvage of Sildenafil Failures With Bremelanotide. J Urol 2023. PMID 36626345
  18. Clayton AH, et al. Safety Profile of Bremelanotide Across the Clinical Development Program. J Womens Health 2022. PMID 35147466
  19. World Anti-Doping Agency. Prohibited List 2026. World Anti-Doping Code International Standard, in force 1 January 2026. WADA Prohibited List 2026